SIU 2017: Outcomes of Pathologic T3a Renal Cell Carcinoma Up-Staged from Small Renal Tumor: Emphasis on Partial Nephrectomy

Lisbon, Portugal ( The prognosis of pathologic T3a renal cell carcinoma (RCC) that is up-staged from a small renal tumor is controversial. The authors evaluated the prognosis of RCC patients who were postoperatively up-staged from clinical T1 to pathologic T3a.

Data of 3,431 patients surgically treated for clinical T1 RCC was retrospectively collected. The survival outcomes were compared using Kaplan-Meier and Cox proportional analyses.

Among the clinical T1 RCC patients, 215 (6.3%) were finally up-staged to pathologic T3a. Patient age (HR 1.030, 95% CI 1.018-1.046, p < 0,001), tumour diameter (HR 1.686, 95% CI 1.551–1.834, p< 0,001), and hilar location (HR 1.765, 95% CI 1.147– 2.715, p = 0.010) were significantly associated with up-staging in multivariable analysis. Kaplan-Meier analyses showed significantly poorer progression-free (PFS), cancer specific (CSS) and overall (OS) survivals (p < 0,001) in up-staged patients. Multivariable Cox regression analysis revealed pathologic up-staging as an independent predictor of inferior progression free survival (PFS) (HR 2.195, 95% CI 1.459-3.300, p< 0.001), CSS (HR 2.238, 95% CI 1252-4.003, p = 0.007), and overall survival (OS) (HR 1.632,95% CI 1,029-2.588, p = 0.037). Subgroup analysis of pathologic T3a showed that there was no significant difference in survival in the partial nephrectomy group compared with the radical nephrectomy group (all p > 0.5).

RCC patients up-staged from clinical T1 to pathologic T3a demonstrated worse postoperative outcomes than those without up-staging. However, partial nephrectomy, compared with radical nephrectomy, resulted in comparable outcomes in these upstaged patients.

Presented by: Young Ju Lee
Affiliation: Seoul National University Hospital, Seoul, South Korea

Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.